Drug Profile
L 806978
Latest Information Update: 13 Mar 2003
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Naphthyridines; Osteoporosis therapies
- Mechanism of Action Bone resorption factor inhibitors; Integrin alphaVbeta3 antagonists; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 13 Mar 2003 No development reported - Preclinical for Osteoporosis in USA (unspecified route)
- 15 Sep 2000 Preclinical development for Osteoporosis in USA (Unknown route)